{ "id": "AIBD-0047", "title": "GB-0669, an AI-designed anti-SARS-CoV-2 antibody, completed a randomized first-in-human trial", "summary": "Phase 1 of the AI-designed antibody GB-0669 in 51 healthy adults showed tolerability, a 54-day half-life and dose-dependent virus neutralization.", "date_observed": "2025-10-08", "date_basis": "source publication", "date_precision": "day", "benefit_status": null, "source_collection": null, "source_entry": null, "account": "Generate Biomedicines used machine-learning models and laboratory testing to optimize the antibody that became GB-0669. The original design study describes a structure-conditioned generative model followed by sequence-to-function models trained on experimental results. The subsequent phase 1 study enrolled 51 healthy adults in Orlando, with 36 receiving GB-0669 and 15 placebo across five dose groups. The authors reported no dose-limiting toxicity and no serious adverse events, although one grade 2 infusion reaction led to interruption of the infusion. Serum testing showed dose-dependent viral neutralization at 600 and 1,200 mg. This was laboratory testing of participant serum, not evidence that patients avoided infection or recovered from illness. The results appeared as an author preprint on October 8, 2025 and in the Journal of Infectious Diseases in July 2026. The trial registry was first posted after the study ended. Its structured allocation field says nonrandomized, while the manuscript describes randomization; that inconsistency remains unresolved.", "category": "general benefit", "unexpected": false, "purpose": "Use generative machine learning to design a therapeutic antibody against a conserved, poorly immunogenic region of the SARS-CoV-2 spike protein.", "system": "Generate Biomedicines generative protein design platform (AI-designed monoclonal antibody GB-0669)", "model_version": null, "developer": "Generate Biomedicines", "deployer": "Generate Biomedicines with contract research organization PPD (phase 1 site)", "location": "Orlando, Florida, United States (phase 1 trial)", "domain": "Antiviral biologics / clinical development", "segment": "Healthy adult volunteers", "benefit_type": "Improved Knowledge Discovery", "taxonomy_note": "An early-phase clinical result is read as knowledge gained rather than a health outcome.", "registry_ids": {}, "ratings": [ { "group": "personal", "depth": null, "reason": "The trial enrolled healthy volunteers and measured safety, pharmacokinetics and serum neutralization; no person obtained a therapeutic benefit." }, { "group": "organizational", "depth": null, "reason": "The source reports a completed phase 1 and a recommendation to proceed to phase 2, not a realized organizational outcome." }, { "group": "societal", "depth": null, "reason": "No population-level benefit is demonstrated; the antibody has not been shown to prevent or treat infection in patients." } ], "ai_role": { "status": "assessed", "statement": "The original design study describes machine-learning optimization of a known antibody using a structure-conditioned generative model and experimentally trained sequence-to-function models. The clinical study evaluates the resulting antibody’s safety and laboratory activity. It does not quantify AI’s advantage over an alternative discovery process or establish a clinical benefit to patients." }, "evidence": [ { "kind": "peer-reviewed study", "citation": "Borriello F, Koh GCKW, Troconiz IF, et al.. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. 2026-07-14. Journal of Infectious Diseases. Published abstract reviewed alongside the full October 8, 2025 author preprint, doi:10.1101/2025.10.07.25337449.", "title": "Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix", "url": "https://doi.org/10.1093/infdis/jiag349", "date": "2026-07-14", "written_by": "makers", "quote": null }, { "kind": "preprint", "citation": "Marden GC, Schmitt KP, Zimmerman MI, et al.. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity. 2025-03-31. Original machine-learning design and preclinical study, cited as reference 14 by the clinical preprint.", "title": "Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity", "url": "https://www.biorxiv.org/content/10.1101/2025.03.30.646023v1", "date": "2025-03-31", "written_by": "makers", "quote": null }, { "kind": "dataset", "citation": "Generate Biomedicines; ClinicalTrials.gov. NCT07050511: GB-0669 in healthy subjects. 2025-07-03. Sponsor-submitted registration posted after trial completion; no posted results. Structured allocation field conflicts with the manuscript’s randomized description.", "title": "NCT07050511: GB-0669 in healthy subjects", "url": "https://clinicaltrials.gov/study/NCT07050511", "date": "2025-07-03", "written_by": "makers", "quote": null } ], "replication": { "produced_by": [ "A generative protein-design platform aimed at the conserved S2 stem helix", "A randomized, placebo-controlled single-ascending-dose trial in healthy adults", "Live-virus neutralization assays on participants' serum" ], "must_hold": [ "Healthy adult volunteers, single intravenous ascending doses from 100 to 2,400 mg", "Live-virus neutralization assay against circulating sarbecoviruses", "Antibody manufactured as in the trial" ], "echoes": [] }, "paired_incident": null, "headline": "Generate Biomedicines' AI-designed GB-0669 completes phase 1", "metric": "dose-dependent serum live-virus neutralization occurred at 600 and 1,200 mg", "comparator": null, "later": { "status": "unknown", "date": "2026-07-14", "note": "The results were subsequently published in the Journal of Infectious Diseases. The authors propose further clinical evaluation; prevention or treatment of infection has not been demonstrated by this study.", "quote": null, "url": "https://doi.org/10.1093/infdis/jiag349" }, "value": null, "developer_country": "United States", "deployer_country": "United States", "unrated_because": null, "brief_notes": null, "brief": null, "revisions": [ { "date": "2026-10-20", "change": "Record drafted from the cited sources.", "source": null, "editor": "AIBD" }, { "date": "2026-10-21", "change": "Country of the developer and the deployer added from the organization's own site or a registry.", "source": "https://generatebiomedicines.com/contact; https://generatebiomedicines.com/contact", "editor": "AIBD" }, { "date": "2026-10-21", "change": "Prose pass: a rating reason, account, the system's part rewritten in shorter sentences with abbreviations expanded; facts, figures and quotations unchanged.", "source": null, "editor": "AIBD" }, { "date": "2026-10-24", "change": "Traced the clinical results to the earlier full author preprint and the AI claim to its original design paper. Corrected chronology, trial location, and registry interpretation.", "source": "https://doi.org/10.1093/infdis/jiag349", "editor": "AIBD" } ], "confidence": "claimed", "shade": "low", "claim_status": "The makers' claim", "claim_basis": "Sources: the makers' peer-reviewed study, the makers' preprint and the makers' dataset. The cited evidence includes no independent source and no finding by a regulator or court.", "profile": { "case_id": "AIBD-0047", "catalog_version": "1.0.0", "source_fingerprint": "e988731b6fe091782e409a8b5d3ea361c97928ffd86b5a247f32818a3dc81cef", "collection_refs": [ { "collection_id": "aibd", "version": "snapshot-8bf7cfec9cb185aa" }, { "collection_id": "aibd", "version": "2026-10-25" } ], "source_ids": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "families": { "strategic assessments": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "record_ids": [] }, "evaluations": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "record_ids": [] }, "monetary observations": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "record_ids": [] }, "institutional decisions": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "record_ids": [] } }, "fields": { "actors[]": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "developer": "Generate Biomedicines", "deployer": "Generate Biomedicines with contract research organization PPD (phase 1 site)" } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "developer", "deployer" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "actors[].ownership_control": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "ai_contribution": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "ai_role": { "status": "assessed", "statement": "The original design study describes machine-learning optimization of a known antibody using a structure-conditioned generative model and experimentally trained sequence-to-function models. The clinical study evaluates the resulting antibody’s safety and laboratory activity. It does not quantify AI’s advantage over an alternative discovery process or establish a clinical benefit to patients." } } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "ai_role" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "ai_relationship": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "category": "general benefit", "ai_role": { "status": "assessed", "statement": "The original design study describes machine-learning optimization of a known antibody using a structure-conditioned generative model and experimentally trained sequence-to-function models. The clinical study evaluates the resulting antibody’s safety and laboratory activity. It does not quantify AI’s advantage over an alternative discovery process or establish a clinical benefit to patients." } } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "category", "ai_role" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "assessments[].alternatives": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "assessments[].assessor_date": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "assessments[].depth": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "assessments[].display_confidence": { "state": "value_present", "value": { "kind": "structured", "data": { "confidence": "low", "evidence_word": "claimed", "claim_status": "The makers' claim", "basis": "Sources: the makers' peer-reviewed study, the makers' preprint and the makers' dataset. The cited evidence includes no independent source and no finding by a regulator or court.", "interpretation": "Existing display rule preserved; the richer outcome-specific confidence question still needs review." } }, "provenance": { "kind": "curatorial", "basis": "Derived from the existing case display properties; not a new evidentiary judgment.", "record_fields": [], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "assessments[].rationale": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "ratings": [ { "group": "personal", "reason": "The trial enrolled healthy volunteers and measured safety, pharmacokinetics and serum neutralization; no person obtained a therapeutic benefit." }, { "group": "organizational", "reason": "The source reports a completed phase 1 and a recommendation to proceed to phase 2, not a realized organizational outcome." }, { "group": "societal", "reason": "No population-level benefit is demonstrated; the antibody has not been shown to prevent or treat infection in patients." } ] } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "ratings" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "assessments[].rubric_version": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "assessments[].status_basis": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "assessments[].target": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "ratings": [ { "group": "personal", "reason": "The trial enrolled healthy volunteers and measured safety, pharmacokinetics and serum neutralization; no person obtained a therapeutic benefit." }, { "group": "organizational", "reason": "The source reports a completed phase 1 and a recommendation to proceed to phase 2, not a realized organizational outcome." }, { "group": "societal", "reason": "No population-level benefit is demonstrated; the antibody has not been shown to prevent or treat infection in patients." } ] } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "ratings" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "availability": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "brief": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "case_kind": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "case_links[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "claims[].evidence_links": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "claims[].evidence_strength": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "claims[].missingness": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "claims[].proposition": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "cross_border_flows[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "decisions[].action_outcome": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "institutional decisions" }, "decisions[].grounds": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "institutional decisions" }, "decisions[].institution_task": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "institutional decisions" }, "decisions[].success_criterion": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "institutional decisions" }, "deployment_stage": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "economics[].amount": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].costs[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].counterfactual": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].currency_price_basis": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].gross_net": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].measure_type": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].period_unit": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].realization": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].recipient_payer": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].return_payback": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "economics[].valuation_method": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "monetary observations" }, "evaluations[].ai_uplift": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].comparator": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].design": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].effect": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].exposure": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].id": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].measurement_method": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].metric": { "state": "not_assessed", "provenance": { "kind": "legacy_record", "basis": "Mapped from the existing case description without a new external source review.", "record_fields": [ "metric" ], "source_refs": [] }, "review_state": "not_assessed", "coverage": "partial", "family": "evaluations", "display": { "answer": "dose-dependent serum live-virus neutralization occurred at 600 and 1,200 mg", "editor_note": "" } }, "evaluations[].reproduction_materials": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].setting_sample": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "evaluations[].uncertainty_limitations": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "evaluations" }, "external_references[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "follow_up[]": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "later": { "status": "unknown", "date": "2026-07-14", "note": "The results were subsequently published in the Journal of Infectious Diseases. The authors propose further clinical evaluation; prevention or treatment of infection has not been demonstrated by this study.", "url": "https://doi.org/10.1093/infdis/jiag349" } } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "later" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "human_oversight": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "id": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "id": "AIBD-0047" } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "id" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "infrastructure_dependencies[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].beneficiaries": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].beneficiary_count": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].benefit_type": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "benefit_type": "Improved Knowledge Discovery", "taxonomy_note": "An early-phase clinical result is read as knowledge gained rather than a health outcome." } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "benefit_type", "taxonomy_note" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "outcomes[].claim": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "account": "Generate Biomedicines used machine-learning models and laboratory testing to optimize the antibody that became GB-0669. The original design study describes a structure-conditioned generative model followed by sequence-to-function models trained on experimental results. The subsequent phase 1 study enrolled 51 healthy adults in Orlando, with 36 receiving GB-0669 and 15 placebo across five dose groups. The authors reported no dose-limiting toxicity and no serious adverse events, although one grade 2 infusion reaction led to interruption of the infusion. Serum testing showed dose-dependent viral neutralization at 600 and 1,200 mg. This was laboratory testing of participant serum, not evidence that patients avoided infection or recovered from illness. The results appeared as an author preprint on October 8, 2025 and in the Journal of Infectious Diseases in July 2026. The trial registry was first posted after the study ended. Its structured allocation field says nonrandomized, while the manuscript describes randomization; that inconsistency remains unresolved.", "benefit_type": "Improved Knowledge Discovery" } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "account", "benefit_type" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "outcomes[].distribution": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].duration": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].id": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].stakeholder_group": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "ratings": [ { "group": "personal", "reason": "The trial enrolled healthy volunteers and measured safety, pharmacokinetics and serum neutralization; no person obtained a therapeutic benefit." }, { "group": "organizational", "reason": "The source reports a completed phase 1 and a recommendation to proceed to phase 2, not a realized organizational outcome." }, { "group": "societal", "reason": "No population-level benefit is demonstrated; the antibody has not been shown to prevent or treat infection in patients." } ] } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "ratings" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "outcomes[].status": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].tradeoffs": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "outcomes[].unexpected": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "unexpected": false, "purpose": "Use generative machine learning to design a therapeutic antibody against a conserved, poorly immunogenic region of the SARS-CoV-2 spike protein." } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "unexpected", "purpose" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "places[]": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "location": "Orlando, Florida, United States (phase 1 trial)", "developer_country": "United States", "deployer_country": "United States" } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "location", "developer_country", "deployer_country" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "purpose": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "purpose": "Use generative machine learning to design a therapeutic antibody against a conserved, poorly immunogenic region of the SARS-CoV-2 spike protein." } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "purpose" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "record_dates": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "date_observed": "2025-10-08", "date_basis": "source publication", "date_precision": "day", "revisions": [ { "date": "2026-10-20", "change": "Record drafted from the cited sources.", "editor": "AIBD" }, { "date": "2026-10-21", "change": "Country of the developer and the deployer added from the organization's own site or a registry.", "source": "https://generatebiomedicines.com/contact; https://generatebiomedicines.com/contact", "editor": "AIBD" }, { "date": "2026-10-21", "change": "Prose pass: a rating reason, account, the system's part rewritten in shorter sentences with abbreviations expanded; facts, figures and quotations unchanged.", "editor": "AIBD" }, { "date": "2026-10-24", "change": "Traced the clinical results to the earlier full author preprint and the AI claim to its original design paper. Corrected chronology, trial location, and registry interpretation.", "source": "https://doi.org/10.1093/infdis/jiag349", "editor": "AIBD" } ] } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "date_observed", "revisions", "date_basis", "date_precision" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "replication.attempts[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "replication.conditions": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "replication": { "produced_by": [ "A generative protein-design platform aimed at the conserved S2 stem helix", "A randomized, placebo-controlled single-ascending-dose trial in healthy adults", "Live-virus neutralization assays on participants' serum" ], "must_hold": [ "Healthy adult volunteers, single intravenous ascending doses from 100 to 2,400 mg", "Live-virus neutralization assay against circulating sarbecoviruses", "Antibody manufactured as in the trial" ], "echoes": [] } } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "replication" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "revision_history[]": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "revisions": [ { "date": "2026-10-20", "change": "Record drafted from the cited sources.", "editor": "AIBD" }, { "date": "2026-10-21", "change": "Country of the developer and the deployer added from the organization's own site or a registry.", "source": "https://generatebiomedicines.com/contact; https://generatebiomedicines.com/contact", "editor": "AIBD" }, { "date": "2026-10-21", "change": "Prose pass: a rating reason, account, the system's part rewritten in shorter sentences with abbreviations expanded; facts, figures and quotations unchanged.", "editor": "AIBD" }, { "date": "2026-10-24", "change": "Traced the clinical results to the earlier full author preprint and the AI claim to its original design paper. Corrected chronology, trial location, and registry interpretation.", "source": "https://doi.org/10.1093/infdis/jiag349", "editor": "AIBD" } ] } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "revisions" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "sector": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "domain": "Antiviral biologics / clinical development", "segment": "Healthy adult volunteers" } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "domain", "segment" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "sources[].access_version": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "sources[].citation_locator": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "evidence": [ { "kind": "peer-reviewed study", "citation": "Borriello F, Koh GCKW, Troconiz IF, et al.. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. 2026-07-14. Journal of Infectious Diseases. Published abstract reviewed alongside the full October 8, 2025 author preprint, doi:10.1101/2025.10.07.25337449.", "title": "Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix", "url": "https://doi.org/10.1093/infdis/jiag349", "date": "2026-07-14", "written_by": "makers" }, { "kind": "preprint", "citation": "Marden GC, Schmitt KP, Zimmerman MI, et al.. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity. 2025-03-31. Original machine-learning design and preclinical study, cited as reference 14 by the clinical preprint.", "title": "Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity", "url": "https://www.biorxiv.org/content/10.1101/2025.03.30.646023v1", "date": "2025-03-31", "written_by": "makers" }, { "kind": "dataset", "citation": "Generate Biomedicines; ClinicalTrials.gov. NCT07050511: GB-0669 in healthy subjects. 2025-07-03. Sponsor-submitted registration posted after trial completion; no posted results. Structured allocation field conflicts with the manuscript’s randomized description.", "title": "NCT07050511: GB-0669 in healthy subjects", "url": "https://clinicaltrials.gov/study/NCT07050511", "date": "2025-07-03", "written_by": "makers" } ] } }, "provenance": { "kind": "source_review", "basis": "Traced the clinical results to the earlier full author preprint and the AI claim to its original design paper. Corrected chronology, trial location, and registry interpretation.", "record_fields": [ "evidence" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "reviewed", "coverage": "partial" }, "sources[].id": { "state": "value_present", "value": { "kind": "identifiers", "identifiers": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "role": "Active evidence sources in reviewed order" }, "provenance": { "kind": "curatorial", "basis": "Assigned to the retained evidence in the dated source review.", "record_fields": [ "evidence" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "reviewed", "coverage": "complete" }, "sources[].language": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "sources[].relationship": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "evidence": [ { "kind": "peer-reviewed study", "citation": "Borriello F, Koh GCKW, Troconiz IF, et al.. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. 2026-07-14. Journal of Infectious Diseases. Published abstract reviewed alongside the full October 8, 2025 author preprint, doi:10.1101/2025.10.07.25337449.", "title": "Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix", "url": "https://doi.org/10.1093/infdis/jiag349", "date": "2026-07-14", "written_by": "makers" }, { "kind": "preprint", "citation": "Marden GC, Schmitt KP, Zimmerman MI, et al.. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity. 2025-03-31. Original machine-learning design and preclinical study, cited as reference 14 by the clinical preprint.", "title": "Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity", "url": "https://www.biorxiv.org/content/10.1101/2025.03.30.646023v1", "date": "2025-03-31", "written_by": "makers" }, { "kind": "dataset", "citation": "Generate Biomedicines; ClinicalTrials.gov. NCT07050511: GB-0669 in healthy subjects. 2025-07-03. Sponsor-submitted registration posted after trial completion; no posted results. Structured allocation field conflicts with the manuscript’s randomized description.", "title": "NCT07050511: GB-0669 in healthy subjects", "url": "https://clinicaltrials.gov/study/NCT07050511", "date": "2025-07-03", "written_by": "makers" } ] } }, "provenance": { "kind": "source_review", "basis": "Traced the clinical results to the earlier full author preprint and the AI claim to its original design paper. Corrected chronology, trial location, and registry interpretation.", "record_fields": [ "evidence" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "reviewed", "coverage": "partial" }, "sources[].upstream_sources": { "state": "value_present", "value": { "kind": "structured", "data": { "origins": [ { "source_refs": [ "AIBD-0047-source-0001" ], "url": "https://doi.org/10.1093/infdis/jiag349", "title": "Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix", "published_on": "2026-07-14", "relationship": "makers", "citation": "Borriello F, Koh GCKW, Troconiz IF, et al.. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. 2026-07-14. Journal of Infectious Diseases. Published abstract reviewed alongside the full October 8, 2025 author preprint, doi:10.1101/2025.10.07.25337449." }, { "source_refs": [ "AIBD-0047-source-0002" ], "url": "https://www.biorxiv.org/content/10.1101/2025.03.30.646023v1", "title": "Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity", "published_on": "2025-03-31", "relationship": "makers", "citation": "Marden GC, Schmitt KP, Zimmerman MI, et al.. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity. 2025-03-31. Original machine-learning design and preclinical study, cited as reference 14 by the clinical preprint." }, { "source_refs": [ "AIBD-0047-source-0003" ], "url": "https://clinicaltrials.gov/study/NCT07050511", "title": "NCT07050511: GB-0669 in healthy subjects", "published_on": "2025-07-03", "relationship": "makers", "citation": "Generate Biomedicines; ClinicalTrials.gov. NCT07050511: GB-0669 in healthy subjects. 2025-07-03. Sponsor-submitted registration posted after trial completion; no posted results. Structured allocation field conflicts with the manuscript’s randomized description." } ], "excluded_republications": [ { "url": "https://clinicaltrials.gov/search?term=GB-0669", "title": "NCT07050511 trial registry record", "published_on": "2024-11-22", "relationship": "Retained as source history; replaced by the original evidence or omitted because no distinct evidence is used for the revised claims", "previous_source_ref": "AIBD-0047-source-0002" } ], "independent_evaluations_of_reported_results": 0, "lead_source_ref": "AIBD-0047-source-0001", "retained_source_order": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "ordering_basis": "The source that directly supports the central case leads. Additional sources contribute the specific evidence or limitations described in claim_lineage.", "claim_lineage": [ { "claim": "Safety, pharmacokinetics, and serum-neutralization findings", "source_chain": [ { "url": "https://doi.org/10.1093/infdis/jiag349", "locator": "Published abstract; July 14 publication with August 20 update metadata", "role": "Peer-reviewed version", "access_status": "Published abstract reviewed; complete journal article inaccessible", "published_on": "2026-07-14" }, { "url": "https://www.medrxiv.org/content/10.1101/2025.10.07.25337449v1", "locator": "Methods: Study Design and Subjects; Results: Safety and Pharmacodynamic; Tables 1–3; Discussion", "role": "Original full author preprint", "access_status": "Full text reviewed through https://www.medrxiv.org/content/early/2025/10/08/2025.10.07.25337449.source.xml", "published_on": "2025-10-08" }, { "url": "https://www.medrxiv.org/content/suppl/2025/10/08/2025.10.07.25337449.DC1/337449_file02.docx", "locator": "Supplemental material, 337449_file02.docx", "role": "Underlying supplementary trial methods", "access_status": "Identified in JATS; download returned an access-denial HTML page" } ], "limitations": [ "Healthy participants; serum-neutralization and modeled neutralizing-index results do not establish patient efficacy", "One grade 2 infusion reaction interrupted dosing", "Published full text and supplementary document not reviewed" ], "source_ref": "AIBD-0047-source-0001" }, { "claim": "AI optimization of GB-0669", "source_chain": [ { "url": "https://www.biorxiv.org/content/10.1101/2025.03.30.646023v1", "locator": "ML-guided optimization of anti-S2 stem helix antibodies; Methods: ML-Guided Protein Optimization", "role": "Original design and preclinical study", "access_status": "Full relevant text reviewed through https://www.biorxiv.org/content/early/2025/03/31/2025.03.30.646023.source.xml", "published_on": "2025-03-31" }, { "url": "https://www.biorxiv.org/content/suppl/2025/03/31/2025.03.30.646023.DC1/646023_file02.pdf", "locator": "Document S1, Figures S1 onward", "role": "Design supplementary material", "access_status": "Download returned an access-denial HTML page" } ], "limitations": [ "Manufacturer-authored design and clinical studies; no independent replication", "Two rounds tested 533 unique sequences; the clinical benefit of the resulting antibody remains unestablished" ], "source_ref": "AIBD-0047-source-0002" }, { "claim": "Trial design, dates, and registration", "source_chain": [ { "url": "https://clinicaltrials.gov/study/NCT07050511", "locator": "History, study dates, designModule, and hasResults; API https://clinicaltrials.gov/api/v2/studies/NCT07050511", "role": "Original sponsor registration", "access_status": "Full relevant text reviewed" } ], "limitations": [ "Study ran July 18, 2023–November 22, 2024; first registry posting July 3, 2025", "Structured allocation NON_RANDOMIZED conflicts with the randomized manuscript description", "Registration is neither independent regulatory confirmation nor clinical results" ], "source_ref": "AIBD-0047-source-0003" } ], "limitations": [ "Published full text and both supplements were inaccessible; the original full preprints were reviewed", "Unresolved trial-allocation discrepancy" ], "chronology_source": { "url": "https://www.medrxiv.org/content/10.1101/2025.10.07.25337449v1", "locator": "Original clinical-results preprint", "role": "First verified public report of these clinical results", "access_status": "Full relevant text reviewed", "published_on": "2025-10-08", "date": "2025-10-08", "title": "First-in-Human Study of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix" } } }, "provenance": { "kind": "source_review", "basis": "Traced the clinical results to the earlier full author preprint and the AI claim to its original design paper. Corrected chronology, trial location, and registry interpretation.", "record_fields": [ "evidence" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "reviewed", "coverage": "partial", "display": { "answer": "The original preprints are available. The published full text and two supplements were inaccessible, and the accounts differ on trial allocation.", "editor_note": "" } }, "strategic_assessments[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial", "family": "strategic assessments" }, "summary": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "summary": "Phase 1 of the AI-designed antibody GB-0669 in 51 healthy adults showed tolerability, a 54-day half-life and dose-dependent virus neutralization.", "account": "Generate Biomedicines used machine-learning models and laboratory testing to optimize the antibody that became GB-0669. The original design study describes a structure-conditioned generative model followed by sequence-to-function models trained on experimental results. The subsequent phase 1 study enrolled 51 healthy adults in Orlando, with 36 receiving GB-0669 and 15 placebo across five dose groups. The authors reported no dose-limiting toxicity and no serious adverse events, although one grade 2 infusion reaction led to interruption of the infusion. Serum testing showed dose-dependent viral neutralization at 600 and 1,200 mg. This was laboratory testing of participant serum, not evidence that patients avoided infection or recovered from illness. The results appeared as an author preprint on October 8, 2025 and in the Journal of Infectious Diseases in July 2026. The trial registry was first posted after the study ended. Its structured allocation field says nonrandomized, while the manuscript describes randomization; that inconsistency remains unresolved." } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "summary", "account" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" }, "systems[].autonomy_permissions": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "systems[].component_role": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "systems[].deployment_configuration": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "systems[].inputs_outputs": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "systems[].model_name": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "systems[].model_version": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "systems[].product_name": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "system": "Generate Biomedicines generative protein design platform (AI-designed monoclonal antibody GB-0669)" } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "system" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "systems[].provider": { "state": "value_present", "value": { "kind": "structured", "data": { "application_developer": "Generate Biomedicines" } }, "provenance": { "kind": "legacy_record", "basis": "Mapped from the existing case description without a new external source review.", "record_fields": [ "developer" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "taxonomy_crosswalks[]": { "state": "not_assessed", "review_state": "not_assessed", "coverage": "partial" }, "title": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "title": "GB-0669, an AI-designed anti-SARS-CoV-2 antibody, completed a randomized first-in-human trial", "headline": "Generate Biomedicines' AI-designed GB-0669 completes phase 1" } }, "provenance": { "kind": "legacy_record", "basis": "Preserved from the existing AIBD record; external sources were not rechecked.", "record_fields": [ "title", "headline" ], "source_refs": [] }, "review_state": "record_mapped", "coverage": "partial" }, "version": { "state": "value_present", "value": { "kind": "identifiers", "identifiers": [ "e988731b6fe091782e409a8b5d3ea361c97928ffd86b5a247f32818a3dc81cef" ], "role": "SHA-256 of normalized original case data" }, "provenance": { "kind": "curatorial", "basis": "Deterministic content version after the October 24, 2026 primary-source review.", "record_fields": [], "source_refs": [], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "complete" }, "workflow": { "state": "value_present", "value": { "kind": "record_fields", "fields": { "account": "Generate Biomedicines used machine-learning models and laboratory testing to optimize the antibody that became GB-0669. The original design study describes a structure-conditioned generative model followed by sequence-to-function models trained on experimental results. The subsequent phase 1 study enrolled 51 healthy adults in Orlando, with 36 receiving GB-0669 and 15 placebo across five dose groups. The authors reported no dose-limiting toxicity and no serious adverse events, although one grade 2 infusion reaction led to interruption of the infusion. Serum testing showed dose-dependent viral neutralization at 600 and 1,200 mg. This was laboratory testing of participant serum, not evidence that patients avoided infection or recovered from illness. The results appeared as an author preprint on October 8, 2025 and in the Journal of Infectious Diseases in July 2026. The trial registry was first posted after the study ended. Its structured allocation field says nonrandomized, while the manuscript describes randomization; that inconsistency remains unresolved.", "replication": { "produced_by": [ "A generative protein-design platform aimed at the conserved S2 stem helix", "A randomized, placebo-controlled single-ascending-dose trial in healthy adults", "Live-virus neutralization assays on participants' serum" ], "must_hold": [ "Healthy adult volunteers, single intravenous ascending doses from 100 to 2,400 mg", "Live-virus neutralization assay against circulating sarbecoviruses", "Antibody manufactured as in the trial" ], "echoes": [] } } }, "provenance": { "kind": "curatorial", "basis": "Updated affected case fields after the dated primary-source review. Unrelated requirement assessments retain their existing status.", "record_fields": [ "account", "replication" ], "source_refs": [ "AIBD-0047-source-0001", "AIBD-0047-source-0002", "AIBD-0047-source-0003" ], "reviewed_on": "2026-10-24" }, "review_state": "record_mapped", "coverage": "partial" } }, "summary": { "total": 91, "addressed": 91, "known": 28, "reviewed": 4, "record_mapped": 24, "not_assessed": 63, "complete": false, "by_state": { "value_present": 28, "not_reported": 0, "unresolved": 0, "not_assessed": 63, "not_applicable": 0, "withheld": 0, "source_unavailable": 0 } } } }